The UK's national resilience is being seriously undermined by limited domestic production and stockpiles of vital medicines, leaving the country exposed to disruption in global supply chains, a House of Lords report has warned.
The National Resilience Committee's report, Are we ready? Building a culture of resilience, published on November 16, identified medicines as one of the essential supplies for which the UK remains heavily dependent on international markets.
It found that around a third of the UK's medicines come from India and another third from the European Union. Around half of the active pharmaceutical ingredients (APIs) used in medicines come from China, with the other half sourced from India.
The committee warned that this dependence could leave the country vulnerable to international conflict, manufacturing disruption and other events affecting supply routes.
It acknowledged that the Department of Health and Social Care (DHSC) maintains medical stockpiles and that suppliers have contractual arrangements to hold buffer stocks, including an eight-week requirement for certain secondary-care medicines. However, it said these measures needed to be reviewed to establish whether they offer sufficient protection during prolonged disruption.
What changes have the Lords recommended?
The committee has called on the government to review existing medicine stockpiles and supplier-held buffer arrangements, including whether pandemic preparedness stockpiles could be used during other national emergencies.
It also wants ministers to identify gaps in coverage and set out how these will be addressed.
A further recommendation is to invest in domestic production capacity for essential medicines and pharmaceutical ingredients, including 6-aminopenicillanic acid (6-APA), an important starting material used in the manufacture of penicillin antibiotics.
The report also calls for closer work with the EU and other international partners to diversify and secure critical supply chains.
The findings highlight concerns about the UK's reliance on overseas manufacturing at a time when medicine availability and pricing remain under pressure. Government price concessions for medicines exceeded 200 for the eighth consecutive month in October, reflecting continued difficulties in sourcing certain products at their listed prices.
What does the industry say about medicines resilience?
The pharmaceutical industry has cautioned against assuming that building larger stockpiles or moving all manufacturing back to the UK would automatically resolve supply vulnerabilities.
Ross Maclagan, head of supply and distribution policy at the Association of the British Pharmaceutical Industry (ABPI), said the UK already had systems to identify and resolve many potential disruptions before they affected patients.
He said around 95 per cent of potential supply disruptions were identified and resolved before patients experienced an impact, while pharmaceutical companies already held buffer stocks of critical medicines.
Maclagan warned that uncoordinated stockpiling could make shortages worse by increasing competition for available supplies. He called instead for better collaboration across the supply chain, earlier warnings of potential disruption and improved two-way data-sharing between industry, the NHS and government.
He also highlighted the importance of longer notice periods on NHS contracts to help manufacturers plan production, alongside proportionate regulatory flexibility when shortages occur.
Community Pharmacy England's director of research and insights, Dr James Davies, said the findings would be familiar to pharmacists who regularly deal with the consequences of supply disruption.
He highlighted particular concerns about antibiotic availability, describing secure access to essential antibiotics as a core part of national resilience. Antibiotics are needed not only for routine infections but also for major surgery and cancer treatment, he said.
The report adds to growing parliamentary scrutiny of medicine supply vulnerabilities. A separate House of Lords Public Services Committee inquiry, published in February, had called for medicine shortages to be treated as a national security issue and recommended improvements to supply notifications and medicine tracking.
For community pharmacies, the challenge is not limited to whether medicines are manufactured or stored in the UK. Disruption anywhere along the supply chain can affect the ability of pharmacy teams to obtain prescribed products and maintain continuity of treatment.
The latest report therefore places responsibility on the government to strengthen domestic capacity while maintaining diverse international supply arrangements. Its recommendations also underline the need for closer co-ordination between manufacturers, wholesalers, the NHS and pharmacies to identify risks before they reach patients.












